Dana-Farber Cancer Institute is a cancer research, treatment, and healthcare organization that provides specialized care for adult and pediatric cancer patients while conducting biomedical and clinical research focused on cancer prevention, diagnosis, and treatment. The institute integrates patient care, scientific research, clinical trials, and medical education, enabling discoveries in oncology to be translated into new therapies and treatment approaches. Its activities span cancer care delivery, laboratory research, translational medicine, population sciences, and physician training programs. The organization operates specialized treatment centers dedicated to a wide range of cancers, including breast, lung, gastrointestinal, hematologic, neurological, gynecologic, and pediatric cancers. It provides services such as medical oncology, radiation oncology, surgical oncology, stem cell transplantation, cellular therapies, genetic testing, palliative care, survivorship programs, and supportive care services. Patients also have access to clinical trials evaluating investigational therapies and emerging treatment strategies. Dana-Farber conducts extensive research across cancer biology, immuno-oncology, genomics, precision medicine, drug discovery, and population health. Its researchers collaborate with academic institutions, healthcare organizations, and industry partners to develop new treatments and improve understanding of cancer mechanisms. The institute also supports clinical research programs that evaluate the safety and effectiveness of novel therapies before they become widely available.